Dementia drugs increase death risks in elderly patients

Share this article:
Atypical anti-psychotic drugs used to treat elderly patients with dementia can also raise their risk of death, according to a new study appearing in The Journal of the American Medical Association.
The study's researchers pooled results of 15 previous studies on atypical anti-psychotics including Eli Lilly's Zyprexa (olanzapine), Janssen's Risperdal (risperidone), AstraZeneca's Seroquel (quetiapine fumarate) and Bristol Myers Squibb's Abilify (aripiprazole).
Among the study's more than 5,000 elderly dementia patients, those taking any of the drugs faced a 54 percent increase in risk of death within 12 weeks of starting the medication, compared with patients taking a placebo.
Meanwhile, the FDA is reported to be considering a regulation to require drug makers to perform longer-term studies of psychiatric medication, including anti-psychotics and antidepressants, before they can be approved for marketing in the U.S.
In a meeting scheduled for Oct. 25, the FDA will ask an advisory committee about its move toward longer-term studies of antidepressants, antipsychotics and other drugs for long-term psychiatric conditions, including how such trials should be designed.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...